Coherus Biosciences Announced That The FDA Approved UDENYCA ONBODY, The Company's On-Body Injector Presentation Of UDENYCA
Portfolio Pulse from Benzinga Newsdesk
Coherus Biosciences has received FDA approval for UDENYCA ONBODY, an on-body injector for pegfilgrastim with a quick five-minute delivery time and a safety-focused retractable needle mechanism designed for cancer patients.
December 26, 2023 | 9:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coherus Biosciences' FDA approval for UDENYCA ONBODY could lead to increased market adoption due to its innovative design, potentially boosting the company's revenues and market share in the pegfilgrastim segment.
FDA approval is a significant milestone for pharmaceutical companies, often leading to increased product adoption and sales. The unique features of UDENYCA ONBODY, such as the five-minute delivery time and retractable needle, are likely to be well-received by healthcare providers and patients, which could translate into a positive impact on Coherus Biosciences' stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100